12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Dymista azelastine/fluticasone regulatory update

Meda said FDA extended the PDUFA date by 3 months for an NDA for Dymista azelastine/fluticasone to treat seasonal allergic rhinitis in patients ages >=12...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >